MPI-INF Logo
Campus Event Calendar

Event Entry

What and Who

Genetic Tumor Progression Scores

Dr. Jörg Rahnenführer
MPI
Habilitationsvortrag und Kolloquium
AG 1, AG 2, AG 3, AG 4, AG 5  
MPI Audience

Date, Time and Location

Tuesday, 20 December 2005
16:00
-- Not specified --
46.1 - MPII
046
Saarbrücken

Abstract

In cancer research, prediction of time to death or relapse is important for a meaningful tumor classification and for selecting appropriate therapies. Traditional biostatistics research considers clinical and histological measurements like tumor stage, tumor volume, or lymph node status, as prognostic markers. The identification of genetic markers that better reflect tumor biology is eminent. Human tumors are often associated with typical chromosomal alterations that accumulate over time. Relating tumor progression to the occurrence of such genetic events helps in the identification of cancer genes and in cancer diagnosis.


We introduce the probabilistic model class of mixtures of oncogenetic trees for estimating typical tumor-specific pathogenetic routes. In these models, progression is characterized by the ordered accumulation of permanent genetic changes. We derive a genetic progression score (GPS) from the tree models that estimates the genetic status of a tumor. Using Cox regression models we demonstrate that the GPS is a medically relevant prognostic factor. For several cancer types, the GPS can be used to discriminate between patient subgroups with different clinical outcome.

Our tree models for estimating tumor progression are currently applied to chromosomal alterations. Extending our approach to changes on gene level will enable a more precise determination of relevant genomic regions and potential target genes.

Contact

--email hidden
passcode not visible
logged in users only

Ruth Schneppen-Christmann, 12/19/2005 12:29 -- Created document.